We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -256.00 | -2.14% | 11,708.00 | 11,710.00 | 11,716.00 | 11,908.00 | 11,678.00 | 11,844.00 | 2,989,208 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5371 | 25.82 | 185.51B |
From Feb 2020 to Feb 2025
By Justina Vasquez
International stocks trading in New York closed mostly higher on Monday.
AstraZeneca PLC was among the companies with ADRs that traded actively.
The BNY Mellon index of American depositary receipts rose 0.2% to 140.65. The European index increased 0.2% to 133.79, the Asian index dropped 0.3% to 159.77, the Latin American index rose 2% to 216.84 and the emerging markets index increased 0.3% to 289.12.
ADRs of AstraZeneca rose 0.23% to $35.15 as a positive recommendation from a European Medicines Agency committee moved the breast-cancer drug Faslodex one step closer to gaining approval for marketing in the European Union and three additional countries. The European Commission must now review the recommendation from the Committee for Medicinal Products for Human Use.
Write to Justina Vasquez at justina.vasquez@wsj.com
(END) Dow Jones Newswires
June 26, 2017 17:50 ET (21:50 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
